Modality
Nanobody
MOA
HPK1i
Target
RET
Pathway
Complement
HCCDLBCL
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
Sep 2017
→ Jul 2027
Phase 2Current
NCT05673682
530 pts·HCC
2017-09→2026-01·Completed
NCT03398729
242 pts·DLBCL
2021-06→2027-07·Active
772 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-212mo agoPh2 Data· HCC
2027-07-101.3y awayPh2 Data· DLBCL
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Complet…
P2
Active
Catalysts
Ph2 Data
2026-01-21 · 2mo ago
HCC
Ph2 Data
2027-07-10 · 1.3y away
DLBCL
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| RHH-5389 | Roche | Preclinical | RET | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ARG-3458 | Argenx | Preclinical | RET |